MIV Therapeutics Inc. (MIVT) is an advanced stage, research and development company pursuing the commercialization of the next-generation biocompatible coatings for stents and other medical devices, and advanced drug delivery systems with the intent of providing healing solutions for cardiovascular disease and other medical conditions. In collaboration with the University of British Columbia (UBC), the Company has developed coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems. Simultaneously, alternative polymer-free coatings and advanced polymeric coatings with enhanced biocompatibility and bioavailability were developed at its wholly owned subsidiary, MIVI Technologies Inc.
(Source: 10-K)
